Pharmacogenetics of neoplastic diseases: New trends

Pharmacological Research

Volumn 49, Issue 4, 2004, Pages 331-342

  Di Paolo, Antonello ^a   Danesi, Romano ^a   Del Tacca, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Activity; Anticancer drugs; Pharmacogenomics; Pharmacoproteomics; Toxicity

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; GEMCITABINE; GUANINE NUCLEOTIDE; IFOSFAMIDE; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; THYMIDYLATE SYNTHASE; TIOGUANINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; APOPTOSIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; COLORECTAL CARCINOMA; DRUG EFFECT; DRUG SENSITIVITY; DRUG TARGETING; DRUG UPTAKE; ENZYME INHIBITION; EVALUATION; EXCISION REPAIR; HEAD AND NECK CARCINOMA; HISTIOCYTOSIS; HUMAN; METASTASIS INHIBITION; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; REVIEW; STOMACH CARCINOMA; TUMOR GROWTH;

EID: 0842328715     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2003.05.002     Document Type: Article

References (122)

1. Thiesing J.T., Ohno-Jones S., Kolibaba K.S., Druker B.J. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood. 96:2000;3195-3199.
2. Ritter C.A., Arteaga C.L. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin. Oncol. 30(1 Suppl. 1):2003;3-11.
3. Anzick S.L., Trent J.M. Role of genomics in identifying new targets for cancer therapy. Oncology. 16(5 Suppl. 4):2002;7-13.
4. Danesi R., De Braud F., Fogli S., Di Paolo A., Del Tacca M. Pharmacogenetic determinants of anti-cancer drug activity and toxicity. Trends Pharmacol. Sci. 22:2001;420-426.
5. Kwok P.-Y. Methods for genotyping single nucleotide polymorphisms. Annu. Rev. Genomics Hum. Genet. 2:2001;235-258.
6. Zhang W., Labordé P.M., Coombes K.R., Berry D.A., Hamilton S.R. Cancer genomics: promises and complexities. Clin. Cancer Res. 7:2001;2159-2167.
7. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11:2000;265-283.
8. Danesi R., De Braud F., Fogli S., De Pas T.M., Di Paolo A., Curigliano G.et al. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol. Rev. 55:2003;57-103.
9. Yeh K.H., Shun C.T., Chen C.L., Lin J.T., Lee W.J., Lee P.H.et al. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer. 82:1998;1626-1631.
10. Nishimura R., Nagao K., Miyayama H., Matsuda M., Baba K., Matsuoka Y.et al. Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res. 19:1999;5621-5626.
11. Horie N., Aiba H., Oguro K., Hojo H., Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20:1995;191-197.
12. Kawakami K., Salonga D., Park J.M., Danenberg K.D., Uetake H., Brabender J.et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin. Cancer Res. 7:2001;4096-4101.
13. Wei X., McLeod H.L., McMurrough J., Gonzalez F.J., Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98:1996;610-615.
14. van Kuilenburg A.B., Muller E.W., Haasjes J., Meinsma R., Zoetekouw L., Waterham H.R.et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+IGA mutation causing DPD deficiency. Clin. Cancer Res. 7:2001;1149-1153.
15. Johnson M.R., Wang K., Diasio R.B. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin. Cancer Res. 8:2002;768-774.
16. van Kuilenburg A.B.P., Haasjes J., Richel D.J., Zoetekouw L., Van Lenthe H., De Abreu R.A.et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil- associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6:2000;4705-4712.
17. Salonga D., Danenberg K.D., Johnson M., Metzger R., Groshen S., Tsao-Wei D.D.et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6:2000;1322-1327.
18. Kitazono M., Takebayashi Y., Ishitsuka K., Takao S., Tani A., Furukawa T.et al. Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem. Biophys. Res. Commun. 253:1998;797-803.
19. Matsuura T., Kuratate I., Teramachi K., Osaki M., Fukuda Y., Ito H. Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas. Cancer Res. 59:1999;5037-5040.
20. Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K.et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer. 34:1998;1274-1281.
21. Schuller J., Cassidy J., Dumont E., Roos B., Durston S., Banken L.et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. 45:2000;291-297.
22. Ishikawa T., Sekiguchi F., Fukase Y., Sawada N., Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 58:1998;685-690.
23. Balis FM, Holcenberg JS, Poplack DG. General principles of chemotherapy. In: Pizzo PA, Poplack DG, editors. Philadelphia: Lippincott-Raven Publishers; 1997. p. 215-72.
24. Allegra CJ. Antifolate. In: Chabner BA, Collins JM, editors. Cancer chemotherapy. Philadelphia: J.B. Lippincott Company; 1990. p. 110-53.
25. Saikawa Y., Knight C.B., Saikawa T., Page S.T., Chabner B.A., Elwood P.C. Decreased expression of the human folate receptor mediates transport-defective methotrexate resistance in KB cells. J. Biol. Chem. 268:1993;5293-5301.
26. Goto Y., Yue L., Yokoi A., Nishimura R., Uehara T., Koizumi S.et al. A novel single-nucleotide polymorphism in the 3′-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin. Cancer Res. 7:2001;1952-1956.
27. Chu E, Allegra C. Antifolates. In: Chabner B, Longo D, editors. Cancer chemotherapy and biotherapy, 2nd ed. Philadelphia, PA: Lippincott-Raven; 1996. p. 109-48.
28. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G.et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase [letter]. Nat. Genet. 10:1995;111-113.
29. Ulrich C.M., Yasui Y., Storb R., Schubert M.M., Wagner J.L., Bigler J.et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 98:2001;231-234.
30. Sirotnak F.M., Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev. Nutr. 19:1999;91-122.
31. Jansen G. Receptor- and carrier-mediated transport systems for folates and antifolates: exploitation for folate-based chemotherapy and immunotherapy. In: Jackman AL, editor. Antifolate drugs in cancer therapy. Totowa, NJ: Humana Press, Inc.; 1999. p. 293-322.
32. 27 carriers. Clin. Cancer Res. 7:2001;3416-3422.
33. Plunkett W., Huang P., Xu Y.Z., Heinemann V., Grunewald R., Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol. 22(Suppl. 11):1995;3-10.
34. Hunsucker S.A., Spychala J., Mitchell B.S. Human cytosolic 5′-nucleotidase I: characterization and role in nucleoside analog resistance. J. Biol. Chem. 276:2001;10498-10504.
35. Bergman A.M., Pinedo H.M., Peters G.J. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist. Update. 5:2002;19-33.
36. Kroep J.R., Loves W.J., van der Wilt C.L., Alvarez E., Talianidis L., Boven E.et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther. 1:2002;371-376.
37. Burton T.R., Kashour T., Wright J.A., Amara F.M. Cellular signaling pathways affect the function of ribonucleotide reductase mRNA binding proteins: mRNA stabilization, drug resistance, and malignancy. Int. J. Oncol. 22:2003;21-31.
38. Goan Y.-G., Zhou B., Hu E., Mi S., Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2- difluorodeoxycytidine in the human KB cancer cell line. Cancer Res. 59:1999;4204-4207.
39. Fukushima M., Fujioka A., Uchida J., Nakagawa F., Takechi T. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur. J. Cancer. 37:2001;1681-1687.
40. Månsson E., Flordal E., Liliemark J., Spasokoukotskaja T., Elford H., Lagercrantz S.et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to floudarabine resistance. Biochem. Pharmacol. 65:2003;237-247.
41. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab. Dispos. 29:2001;601-605.
42. McLeod H.L., Evans W.E. Pharmacogenetics: unlocking the human genome for better drug therapy. Annu. Rev. Pharmacol. Toxicol. 41:2001;101-121.
43. Otterness D., Szumlanski C., Lennard L., Klemetsdal B., Aarbakke J., Park-Hah J.O.et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmacol. Ther. 62:1997;60-73.
44. Coulthard S.A., Howell C., Robson J., Hall A.G. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. Blood. 92:1998;2856-2862.
45. Yan L., Zhang S., Eiff B., Szumlanski C.L., Powers M., O'Brien J.et al. Thiopurine methyltransferase (TPMT) promoter variable number tandem repeat (VNTR) polymorphism: genotype-phenotype correlation analysis for 1211 patients. Clin. Pharmacol. Ther. 68:2000;210-219.
46. Evans W.E., Hon Y.Y., Bomgaars L., Coutre S., Holdsworth M., Janco R.et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathiopurine. J. Clin. Oncol. 19:2001;2293-2301.
47. Rougier P., Mitry E. Review of the role of CPT-11 in the treatment of colorectal cancer. Clin. Colorectal. Cancer. 1:2001;87-94.
48. Chabot G.G. Clinical pharmacokinetics of irinotecan. Clin. Pharmacokinet. 33:1997;245-259.
49. Pommier Y., Pourquier P., Fan Y., Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta. 1400:1998;83-106.
50. Larsen A.K., Skladanowski A. Cellular resistance to topoisomerase- targeted drugs: from drug uptake to cell death. Biochim. Biophys. Acta. 1400:1998;257-274.
51. Yanase K., Sugimoto Y., Andoh T., Tsuruo T. Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of a camptothecin resistance. Int. J. Cancer. 81:1999;134-140.
52. Dingemans A.-M.C., Pinedo H.M., Giaccone G. Clinical resistance to topoisomerase-targeted drugs. Biochim. Biophys. Acta. 1400:1998;275-288.
53. Cummings J., Boyd G., Ethell B.T., Macpherson J.S., Burchell B., Smyth J.F., Jodrell D.I. Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem. Pharmacol. 63:2002;607-613.
54. Iyer L., Hall D., Das S., Mortell M.A., Ramirez J., Kim S.et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 65:1999;576-582.
55. Burchell B., Soars M., Monaghan G., Cassidy A., Smith D., Ethell B. Drug-mediated toxicity caused by genetic deficiency of UDP- glucuronosyltransferases. Toxicol. Lett. 112-113:2000;333-340.
56. Iyer L., Das S., Janisch L., Wen M., Ramirez J., Karrison T.et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2:2002;43-47.
57. Ando Y., Saka H., Ando M., Sawa T., Muro K., Ueoka H.et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60:2000;6921-6926.
58. Eisenhauer E.A., Vermorken J.B. The taxoids: comparative clinical pharmacology and therapeutic potential. Drugs. 55:1998;5-30.
59. Rao S., Krauss N.E., Heerding J.M., Swindell C.S., Ringel I., Orr G.A.et al. 3′-(p-Azidobenzamido)taxol photolabels the N-terminal 31 amino acids of β-tubulin. J. Biol. Chem. 269:1994;3132-3134.
60. Rao S., Orr G.A., Chandary A.G., Kingston D.G., Horwitz S.B. Characterization of the taxol binding site on the microtubule. 2-(m-azidobenzoyl)taxol photolabels a peptide (aminoacids 217-231) of β-tubulin. J. Biol. Chem. 270:1995;20235-20238.
61. Giannakakou P., Gussio R., Nogales E., Downing K.H., Zaharevitz D., Bollbuck B.et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. U.S.A. 97:2000;2904-2909.
62. Ranganathan S., Salazar H., Benetatos C.A., Hudes G.R. Immunohistochemical analysis of beta-tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy. Prostate. 30:1997;263-268.
63. Banerjee A. Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun. 293:2002;598-601.
64. Kavallaris M., Kuo D.Y.-S., Burkhart G.A., Regl D.L., Norris M.D., Haber M.et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest. 100:1997;1282-1293.
65. Blade K., Menick D.R., Cabral F. Overexpression of class I, II or IV β-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel. J. Cell Sci. 112:1999;2213-2221.
66. Montgomery R.B., Guzman J., O'Rourke D.M., Stahl W.L. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters β-tubulin isotype expression. J. Biol. Chem. 275:2000;17358-17363.
67. Kamazawa S., Kigawa J., Kanamori Y., Itamochi H., Sato S., Iba T.et al. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol. Oncol. 86:2002;171-176.
68. Walle T., Walle U.K., Kumar G.N., Bhalla K.N. Taxol metabolism and disposition in cancer patients. Drug Metab. Dispos. 23:1995;506-512.
69. Jamis-Dow C.A., Klecker R.W., Katki A.G., Collins J.M. Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother. Pharmacol. 36:1995;107-114.
70. Dai D., Zeldin D.C., Blaisdell J.A., Chanas B., Coulter S.J., Ghanayem B.I.et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 11:2001;597-607.
71. Dai D., Tang J., Rose R., Hodgson E., Bienstock R.J., Mohrenweiser H.W. et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 299:2001;825-831.
72. Soyama A., Saito Y., Hanioka N., Murayama N., Nakajima O., Katori N.et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol. Pharm. Bull. 24:2001;1427-1430.
73. Goh B.C., Lee S.C., Wang L.Z., Fan L., Guo J.Y., Lamba J.et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. 20:2002;3683-3690.
74. Fleming R.A. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy. 17:1997;146S-154S.
75. Huang Z., Roy P., Waxman D.J. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol. 59:2000;961-972.
76. Jinno H., Tanaka-Kagawa T., Ohno A., Makino Y., Matsushima E., Hanioka N.et al. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab. Dispos. 31:2003;398-403.
77. Weber WW. Pharmacogenetics. Oxford: Oxford University Press; 1999.
78. Takebayashi Y., Nakayama K., Kanzaki A., Miyashita H., Ogura O., Mori S.et al. Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors. Cancer Lett. 174:2001;115-125.
79. Zunino F., Perego P., Pilotti S., Pratesi G., Supino R., Arcamone F. Role of apoptotic response in cellular resistance to cytotoxic agents. Pharm. Ther. 76:1997;177-185.
80. Feng L., Achanta G., Pelicano H., Zhang W., Plunkett W., Huang P. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. Int. J. Mol. Med. 5:2000;597-604.
81. Bosari S., Viale G. The clinical significance of p53 aberrations in human tumors. Virchows Arch. 427:1995;229-241.
82. Wang Y.-C., Chen C.-Y., Chen S.-K., Chang Y.-Y., Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin. Cancer Res. 5:1999;129-134.
83. Goh H.S., Yao J., Smith D.R. p53 point mutation and survival in colorectal cancer patients. Cancer Res. 55:1995;5217-5221.
84. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L.et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104:1999;263-269.
85. Reles A., Wen W.H., Schmider A., Gee C., Runnebaum I.B., Kilian U.et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin. Cancer Res. 7:2001;2984-2997.
86. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
87. Jones R.H., Vasey P.A. New directions in testicular cancer; molecular determinants of oncogenesis and treatment success. Eur. J. Cancer. 39:2003;147-156.
88. Nita M.E., Nagawa H., Tominaga O., Tsuno N., Fujii S., Sasaki S.et al. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br. J. Cancer. 78:1998;986-992.
89. Vogelbaum M.A., Tong J.X., Perugu R., Gutmann D.H., Rich K.M. Overexpression of bax in human glioma cell lines. J. Neurosurg. 91:1999;483-489.
90. Saxena A., Moshynska O., Sankaran K., Viswanathan S., Sheridan D.P. Association of a novel single nucleotide polymorphism, G(-248)A, in the 5′-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance. Cancer Lett. 187:2002;199-205.
91. Eastman A. Characterization of the adducts produced in DNA be cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). Biochemistry. 22:1983;3927-3933.
92. Fichtinger-Schepman A.M.J., van der Veer J.L., den Hartog J.H., Lohman P.H., Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry. 24:1985;707-713.
93. McHugh P.J., Spanswick V.J., Hartley J.A. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2:2001;483-490.
94. Monzo M., Rosell R., Taron M. Drug resistance in non-small cell lung cancer. Lung Cancer. 34:2001;S91-S94.
95. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M.et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8:2002;2286-2291.
96. Rosell R., Fossella F., Milas L. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer. 38:2002;S43-S49.
97. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., Danenberg K.D.et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19:2001;4298-4304.
98. Park D.J., Stoehlmacher J., Zhang W., Tsao-Wei D.D., Groshen S., Lenz H.J. A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 61:2001;8654-8658.
99. Ferry K.V., Hamilton T.C., Johnson S.W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells. Role of ERCC1-XPF. Biochem. Pharmacol. 60:2000;1305-1313.
100. Damia G., Guidi G., D'Incalci M. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. Eur. J. Cancer. 34:1998;1783-1788.
101. 6-methylguanine in DNA to inactivation by alkylating agents including chlorethyinitrosoureas. Cancer Res. 44:1984;2467-2474.
102. Middleton M.R., Margison G.P. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol. 4:2003;37-44.
103. 6-methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bischloroethylnitrosourea: a Southwest Oncology Group Study. J. Clin. Oncol. 16:1998;3310-3315.
104. Friedman H.S., Kerby T., Calvert H. Temozolomide and treatment of malignant glioma. Clin. Cancer Res. 6:2000;2585-2597.
105. Bredel M., Zentner J. Brain-tumour drug resistance: the bare essentials. Lancet Oncol. 3:2002;397-406.
106. Lien S., Larsson A.-K., Mannervik B. The polymorphic human glutathione transgerase T1-1, the most efficient glutathione transferase in the denitrosation and inactivation of the anticancer drug 1, 3-bis(2-chloroethyl)-1- nitrosourea. Biochem. Pharmacol. 63:2002;191-197.
107. Pandya U., Srivastava S.K., Singhal S.S., Pal A., Awasthi S., Zimniak P.et al. Activity of allelic variants of Pi class human glutathione S-transferase toward chlorambucil. Biochem. Biophys. Res. Commun. 278:2000;258-262.
108. Gulick A.M., Fahl W.E. Mammalian glutathione S-transferase: regulation of an enzyme system to achieve chemotherapeutic efficacy. Pharmacol. Ther. 66:1995;237-257.
109. Naoe T., Tagawa Y., Kiyoi H., Kodera Y., Miyawaki S., Asou N.et al. Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy. Leukemia. 16:2002;203-208.
110. Yang P., Yokomizo A., Tazelaar H.D., Marks R.S., Lesnick T.G., Miller D.L.et al. Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes. Lung Cancer. 35:2002;221-229.
111. Bodó A., Bakos E., Szeri F., Váradi A., Sarkadi B. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol. Lett. 140-141:2003;133-143.
112. Klein I., Sarkadi B., Varadi A. An inventory of the human ABC proteins. Biochim. Biophys. Acta. 1461:1999;237-262.
113. Larsen A.K., Escargueil A.E., Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol. Ther. 85:2000;217-229.
114. Lage H., Dietel M. Effect of the breast-cancer resistance protein on atypical multidrug resistance. Lancet Oncol. 1:2000;169-175.
115. Borst P., Evers R., Kool M., Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92:2000;1295-1302.
116. Nakamura T., Sakaeda T., Ohmoto N., Tamura T., Aoyama N., Shirakawa T.et al. Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab. Dispos. 30:2002;4-6.
117. Brinkmann U., Roots I., Eichelbaum M. Pharmacogenetics of the human drug transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Disease Treat. 6:2001;835-839.
118. Sauer G., Kafka A., Grundmann R., Kreienberg R., Zeillinger R., Deissler H. Basal expression of the multidrug resistance gene 1 (MDR-1) is associated with the TT genotype at the polymorphic site C3435T in mammary and ovarian carcinoma cell lines. Cancer Lett. 185:2002;79-85.
119. Meschini S., Marra M., Calcabrini A., Monti E., Gariboldi M., Dolfi E.et al. Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells. Toxicol. in Vitro. 16:2002;389-398.
120. Zurita A.J., Diestra J.E., Condom E., Garcia Del Muro X., Scheffer G.L., Scheper R.J.et al. Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours. Br. J. Cancer. 88:2003;879-886.
121. Jain K.K. Applications of proteomics in oncology. Pharmacogenomics. 1:2000;385-393.
122. Lin X., Parsels L.A., Voeller D.M., Allegra C.J., Maley G.F., Maley F.et al. Characterization of a cis-acting regulatory element in the protein coding region of thymidylate synthase mRNA. Nucleic Acids Res. 28:2000;1381-1389.